Insider Transactions in Q1 2022 at Intra Cellular Therapies, Inc. (ITCI)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 31
2022
|
Rory B Riggs |
BUY
Grant, award, or other acquisition
|
Direct |
257
+0.33%
|
$15,677
$61.19 P/Share
|
|
Mar 31
2022
|
Robert L Van Nostrand |
BUY
Grant, award, or other acquisition
|
Direct |
126
+1.39%
|
$7,686
$61.19 P/Share
|
|
Mar 18
2022
|
Rory B Riggs |
SELL
Open market or private sale
|
Indirect |
20,637
-61.87%
|
$1,238,220
$60.99 P/Share
|
|
Mar 17
2022
|
Rory B Riggs |
SELL
Open market or private sale
|
Indirect |
141,499
-50.59%
|
$8,489,940
$60.2 P/Share
|
|
Mar 16
2022
|
Rory B Riggs |
SELL
Open market or private sale
|
Indirect |
64,534
-15.21%
|
$3,807,506
$59.13 P/Share
|
|
Mar 09
2022
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
38,925
+3.32%
|
$77,850
$2.84 P/Share
|
|
Mar 08
2022
|
Joel S Marcus |
SELL
Open market or private sale
|
Indirect |
15,000
-18.51%
|
$780,000
$52.57 P/Share
|
|
Mar 07
2022
|
Joel S Marcus |
SELL
Open market or private sale
|
Indirect |
5,000
-10.21%
|
$270,000
$54.52 P/Share
|
|
Mar 04
2022
|
Suresh K. Durgam EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,860
-14.32%
|
$212,300
$55.52 P/Share
|
|
Mar 02
2022
|
Suresh K. Durgam EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,177
-13.41%
|
$233,912
$56.98 P/Share
|
|
Feb 24
2022
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
22,589
-0.68%
|
$1,152,039
$51.63 P/Share
|
|
Feb 24
2022
|
Lawrence J. Hineline SVP of Finance, CFO |
SELL
Open market or private sale
|
Direct |
7,454
-80.92%
|
$380,154
$51.65 P/Share
|
|
Feb 24
2022
|
Michael Halstead EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
7,906
-73.51%
|
$411,112
$52.0 P/Share
|
|
Feb 24
2022
|
Mark Neumann EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
7,906
-5.2%
|
$411,112
$52.1 P/Share
|
|
Feb 24
2022
|
Suresh K. Durgam EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,046
-3.97%
|
$210,392
$52.17 P/Share
|
|
Feb 23
2022
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
22,589
+1.98%
|
-
|
|
Feb 23
2022
|
Lawrence J. Hineline SVP of Finance, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,454
+50.0%
|
-
|
|
Feb 23
2022
|
Michael Halstead EVP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
7,906
+50.0%
|
-
|
|
Feb 23
2022
|
Mark Neumann EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,906
+12.93%
|
-
|
|
Feb 23
2022
|
Suresh K. Durgam EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,906
+18.35%
|
-
|
|
Feb 22
2022
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
27,847
-1.25%
|
$1,531,585
$55.36 P/Share
|
|
Feb 22
2022
|
Lawrence J. Hineline SVP of Finance, CFO |
SELL
Open market or private sale
|
Direct |
10,443
-77.85%
|
$574,365
$55.36 P/Share
|
|
Feb 22
2022
|
Michael Halstead EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
11,139
-79.58%
|
$612,645
$55.33 P/Share
|
|
Feb 22
2022
|
Mark Neumann EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
11,139
-10.39%
|
$612,645
$55.22 P/Share
|
|
Feb 22
2022
|
Suresh K. Durgam EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,177
-6.85%
|
$229,735
$55.16 P/Share
|
|
Feb 18
2022
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
27,847
+2.42%
|
-
|
|
Feb 18
2022
|
Lawrence J. Hineline SVP of Finance, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,443
+50.0%
|
-
|
|
Feb 18
2022
|
Michael Halstead EVP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
11,139
+50.0%
|
-
|
|
Feb 18
2022
|
Mark Neumann EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,139
+16.47%
|
-
|
|
Feb 18
2022
|
Suresh K. Durgam EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,354
+20.98%
|
-
|
|
Jan 18
2022
|
Suresh K. Durgam EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,223
-21.22%
|
$261,366
$42.03 P/Share
|
|
Jan 10
2022
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
41,896
-1.24%
|
$1,675,840
$40.87 P/Share
|
|
Jan 10
2022
|
Lawrence J. Hineline SVP of Finance, CFO |
SELL
Open market or private sale
|
Direct |
19,639
-63.67%
|
$785,560
$40.82 P/Share
|
|
Jan 10
2022
|
Michael Halstead EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
19,639
-62.4%
|
$785,560
$40.89 P/Share
|
|
Jan 10
2022
|
Mark Neumann EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
20,948
-11.56%
|
$837,920
$40.88 P/Share
|
|
Jan 10
2022
|
Suresh K. Durgam EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,870
-6.62%
|
$274,800
$40.65 P/Share
|
|
Jan 08
2022
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
41,896
+3.56%
|
-
|
|
Jan 08
2022
|
Lawrence J. Hineline SVP of Finance, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
19,639
+50.0%
|
-
|
|
Jan 08
2022
|
Michael Halstead EVP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
19,639
+50.0%
|
-
|
|
Jan 08
2022
|
Mark Neumann EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,948
+24.01%
|
-
|
|
Jan 08
2022
|
Suresh K. Durgam EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,093
+26.56%
|
-
|